This study aimed to evaluate the safety of two glucose-lowering medications, namely, SGLT-2is and GLP-1 RAs, which are administered for treating patients with T2DM in a real-world setting, according to the standard-of-care regimen with maximum tolerated doses, in association with other antidiabetic, BP-lowering, and lipid-lowering medications. This evidence concerns the gene GLP1R and type 2 diabetes mellitus.